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Long non-coding RNAs compose an important level of epigenetic regulation in normal physiology 
and disease. Despite the plethora of publications of lncRNAs in human cancer, the landscape is still 
unclear. 
Methods 
Microarray analysis in 44 NSCLC paired specimens was followed by qPCR-based validation in 29 
(technical) and 38 (independent) tissue pairs. Cross-validation of the selected targets was achieved 
in 850 NSCLC tumours from TCGA datasets. 
Results 
Twelve targets were successfully validated by qPCR (upregulated: FEZF1-AS1, LINC01214, LINC00673, 
PCAT6, NUTM2A-AS1, LINC01929; downregulated: PCAT19, FENDRR, SVIL-AS1, LANCL1-AS1, 
ADAMTS9-AS2 and LINC00968). All of them were successfully cross-validated in the TCGA datasets. 
Abnormal DNA methylation was observed in the promoters of FENDRR, FEZF1-AS1, and SVIL-AS1. 
FEZF1-AS1 and LINC01929 were associated with survival in the TCGA set. 
Conclusions 
Our study provides through multiple levels of internal and external validation, a comprehensive list 
of dysregulated lncRNAs in NSCLC. We therefore envisage this dataset to serve as an important 
source for the lung cancer research community assisting future investigations on the involvement of 
lncRNAs in the pathogenesis of the disease and providing novel biomarkers for diagnosis, prognosis 





Long non-coding RNAs (lncRNAs) comprise a heterogeneous group of transcripts > 200 nucleotides 
with no protein coding capacity. In relation to their topography of the closest protein-coding gene, 
lncRNAs have been broadly classified into: sense, antisense, bidirectional, intronic, and intergenic 
lncRNAs.1 They are largely transcribed by RNA polymerase II, spliced, 5’capped, polyadenylated, and 
regulated at multiple levels similarly to the mRNAs.2 GENCODE release v29 reports 16,066 lncRNA 
transcripts.3 Although the function of the majority of lncRNAs is still largely unknown, evidence 
reveals their participation in many regulatory pathways4, including chromatin organization, 
transcriptional regulation, post-transcriptional and post-translational processing.5 These functions 
are exerted by acting as guides, tethers, decoys, scaffolds, competitive endogenous RNAs and miRNA 
sponges.4 In general, lncRNAs show lower expression levels, significantly shorter transcript half-lives 
and higher cell and tissue specificity than mRNAs.1, 6, 7 
Dysregulation of lncRNA expression appears to be extensive in cancer, where they act either as 
oncogenes or tumour repressors.8-10 In the past few years, several pan-cancer transcriptomic 
analyses have been carried out after thorough realignment and reannotation of thousands of RNA-
seq libraries retrieved from TCGA, providing an overview of lncRNA transcriptional alterations in 
different human cancers. These studies suggest that a) lncRNAs are frequently dysregulated in 
tumours, b) many of these alterations are highly tumour-specific and c) they are often associated 
with other cancer-related (epi)genetic alterations.9, 10 
Lung cancer is the most frequent cause of cancer-related deaths and non-small cell lung cancer 
accounts for the majority of the reported cases.11 Early screening and improved therapies are critical 
unmet clinical needs12 and the field of lncRNAs has attracted a lot of interest in an effort to identify 
novel diagnostic biomarkers and therapeutic targets. Analysis of publicly available RNA-seq data 
indicated 111 intergenic lung cancer-associated lncRNAs that were differentially expressed between 
tumour and adjacent normal lung tissue.13 Furthermore, following a pan-cancer analysis of RNA-seq 
data from 7 additional TCGA solid tumour types, 58 of these were shown to be specific to lung 
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cancer. To date, there are a number of additional studies analysing publicly available lncRNA 
expression data in lung cancer14-16 and fewer attempting validation in independent sample sets.17-19 
However, despite the plethora of published papers, the lncRNA landscape in NSCLC is far from 
comprehensive, mainly because of the limited independent validation, inconsistency of targets and 
sample sets. In this study, we undertook a lncRNA transcriptome-wide microarray approach and 
performed both technical and biological validation of a number of highly differential expressed 
lncRNA targets. Qualified targets  from this process were cross validated in TCGA datasets. 
Expression was also tested in a series of NSCLC cell lines. Finally, we investigated the DNA 
methylation status of those dysregulated lncRNAs bearing CpG islands in their promoters. 
 
Materials and Methods 
Patients and samples 
A set of 82 NSCLC patients from the Liverpool Lung Project (LLP) were used for expression analysis. 
All patients were recruited, following voluntary informed consent, from Liverpool Heart and Chest 
Hospital, in accordance with the Declaration of Helsinki. Ethical approval was obtained from the 
Liverpool Central Research Ethics Committee (ref 97/141). Frozen tissues were macrodissected to 
ensure >70% tumour content. For DNA methylation analysis, we utilized DNAs from 129 tumour and 
36 normal samples available from previous studies.20, 21 Demographic and clinical characteristics of 
the cancer patients are summarized in Supplementary Table S1. 
Analysis of the Cancer Genome Atlas (TCGA) expression data 
Clinical and gene expression data was downloaded from the Genomics Data Commons (GDC) data 
portal using GDC Data Transfer Tool from the following The Cancer Genome Atlas (TCGA) datasets: 
TCGA-LUAD (Lung adenocarcinoma; N=585) and TCGA-LUSC (Lung squamous cell carcinoma; N=504). 
Patients with prior malignancies, subject to prior treatment and/or synchronous tumours were 
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removed from our analysis. The main demographic and clinical characteristics of the TCGA patients 
analysed are summarized in Supplementary Table S2. Normalised gene expression values (FPKM-UQ; 
Fragments Per Kilobase of transcript per Million mapped reads upper quartile) were employed. 
Cell lines and growth conditions 
Thirteen NSCLC cell lines (A549, Calu-1, Calu-3, Calu-6, COR-L23, DMS53, H358, H2073, HTB-59, HTB-
182, LUDLU-1, SK-LU-1 and SK-MES-1) and a non-tumorigenic human foetal lung fibroblast cell line 
(IMR-90) were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM)/Ham’s Nutrient Mixture F-
12 (1 : 1) containing 10% foetal bovine serum (Sigma-Aldrich, Gillingham, UK) at 37 °C and 5% CO2. 
All cell lines were mycoplasma tested (e-Myco™ plus Kit, iNtRON Biotechnology, Gyeonggi-do, 
Korea) and authenticated (GenePrint 10 System, Promega, Southampton, UK). 
RNA isolation 
Total RNA was extracted from both tissue (10X 10 μm thick) and cell lines using the Direct-zol mini 
kit (ZymoResearch, Irvine, CA, USA). RNA concentration and purity were determined on a NanoDrop 
ND-1000 spectrophotometer (Thermo Fisher Scientific, Hemel Hempstead, UK). RNA integrity was 
determined using the RNA 6000 Nano Lab-on-a-Chip kit on a Bioanalyzer 2100 (Agilent Technologies, 
Warrington, UK). 
lncRNA array profiling 
lncRNA profiling was performed on 44 normal-tumour pairs, using an Agilent Custom 8x60K 
expression array (AMADID: 047718) designed by the GENCODE consortium based on the Gencode 
v15 catalogue of human lncRNA. 
Sample labelling and array hybridization were performed according to the Two-Color Microarray-
Based Gene Expression Analysis—Low Input Quick Amp Labeling—protocol version 6.7 (Agilent 
Technologies, Warrington, UK). Tumour samples were labelled with Cy3 and Cy5 was used with 
normal tissue. The labelled cRNA was hybridized to the Agilent SurePrint G3 gene expression 8 × 60 K 
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microarray and scanned on an Agilent G2565CA microarray scanner at 100% R+G PMT, 3μm 
resolution and 20 bit TIFF with no XDR. Agilent’s Feature Extraction 11.0.1.1 software was used to 
analyse acquired array images and extract intensity data. The microarray data have been deposited 
in the Gene Expression Omnibus (GEO) database (GSE130740). 
lncRNA RT–qPCR 
Technical validation of the selected targets was performed in 29/44 array samples. Biological 
validation was undertaken on 38 independent NSCLC normal-tumour pairs. Additionally, the 
expression levels of the validated lncRNA targets were assessed in 14 cell lines. One µg total RNA 
was reverse transcribed (QuantiTect Reverse Transcription Kit, Qiagen, Crawley, UK) according to the 
manufacturer’s instructions. Quantitative real-time PCR was performed in triplicate using QuantiTect 
probe PCR mastermix (Qiagen, Crawley, UK). Primers and probes as well as the thermal profiles for 
each lncRNA qPCR assay are provided in Supplementary Table S3. lncRNA expression was quantified 
using the 2-ΔΔCt method and TBP as endogenous control. 
DNA extraction and methylation analysis 
DNA has been previously isolated.20, 21 Pyrosequencing methylation analysis assays were designed 
for those lncRNAs harbouring a CpG island in their promoter (i.e. FENDRR, FEZF1-AS1, LIN00673, 
NUTM2A-AS1, PCAT6, RNF139-AS1, SVIL-AS1). One μg of DNA was bisulphite-converted (EZ-96 DNA 
Methylation-Gold Kit, ZymoResearch, Irvine, CA, USA). DNA methylation analysis was performed by 
pyrosequencing (Qiagen, Crawley, UK) as previously described.20 Primers and PCR thermal profiles 
for each pyrosequencing assay are provided in Supplementary Table S4. 
Statistical analysis 
Statistical analysis of the microarray. Raw data were corrected for background noise using the 
normexp method and normalized using the loess method in Limma.22 Differential expression analysis 
was carried out on non-control probes using linear models and robust empirical Bayes moderated t-
7 
 
statistics.23 We compared lung tumours to their matched normal tissue to identify NSCLC-specific 
lncRNA transcriptional signatures. P-values were adjusted to control the false discovery rate (FDR) 
below 5% using the Benjamini and Hochberg method. Differentially expressed genes were identified 
using the double-filtering criterion: adjusted p-value (FDR) <0.01 and an absolute log2 fold change 
(absolute log2 fold-change) >0.5. All statistical analyses were performed with Bioconductor in the R 
statistical environment.24 For the visualization of the 44 pairs of tissue (tumour and normal) data 
were subtracted for Cy3 and Cy5 separately after background correction, normalized using 
cyclicloess method, log2 transformed and plotted using the coolmap function in Limma.22 
Validation of differentially expressed lncRNA by RT-qPCR. lncRNA targets showing the highest 
differential expression between tumour and normal tissues were selected for further biological 
validation. Wilcoxon signed rank tests were used to establish statistically significant changes 
between the paired tumours and adjacent tissues while Mann-Whitney U and Kruskal-Wallis H tests 
were used to assess possible associations between expression and clinicopathological features in 
tumours. ROC curves and AUC were calculated for all the validated targets following binary logistic 
regression analysis. For each lncRNA, the patient cohort was dichotomized into low and high 
expression subgroups using the relative quantity (RQ) median;patients’ survival was calculated using 
the log rank test and plotted using Kaplan-Meier curves. 
DNA methylation analysis. Hypermethylation thresholds were calculated using the 95% reference 
interval (mean + 2× SD) of the normal sample values. Differences between the methylation status 
(hypermethylated vs normal) of tumours and clinicopathological features were assessed using Chi-
square and Fisher’s exact tests. 
Analysis of differentially expressed lncRNAs in the TCGA dataset. Mann-Whitney U tests were used to 
establish statistically significant changes between the tumours and normal tissues. Associations 
between expression and clinicopathological features in tumours were assessed using Mann-Whitney 
U and Kruskal-Wallis H tests. Pairwise multiple comparisons were carried out using Dunn’s post hoc 
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test and p-values were adjusted using the Bonferroni error correction. Patients’ survival was 
calculated as described above. 
 
Results 
Discovery of aberrant lncRNA expression profiles in NSCLC 
On the Gencode v15 microarray, each of the 17,535 randomly selected protein coding and 22,001 
lncRNA transcripts is targeted by two probes. Three samples that were analysed in duplicate and 
hybridized on separate arrays were used as technical replicates. Technical replicates showed a 
strong pairwise Pearson correlation coefficient (r ≥ 0.86, p-value <10-16). An initial comparison 
between the lncRNA expression profiles of NSCLC tissue and adjacent normal tissue using 
unsupervised hierarchical clustering analysis showed that samples could be neatly classified based 
on the expression levels of antisense and lincRNAs (Supplementary Fig. S1C and S1B) as well as 
protein coding transcripts (Supplementary Fig. S1A). Gene expression analysis identified the 
following numbers of differentially expressed transcripts in the NSCLC vs normal comparison: 581 
(down) and 368 (up) lincRNAs, 541 (down) and 403 (up) antisense RNAs as well as 1,992 (up) and 
1,448 (down) protein-coding RNAs, (Supplementary Table S5). In this study, we focused only in the 
validation of the lncRNAs (lincRNA and antisense RNA transcripts). 
Validation of differentially expressed lncRNAs 
The selection criteria for the validation step included the p-value, fold-change and the clarity of 
annotation of the sequences. Regarding the latter, validation was performed only for targets where 
the probe sequence matched the location or Ensembl_ID indicated in the array manifest. For the 
validation step, we selected fourteen targets across a range of adjusted p-values (7.6 ×10-3 to 2.7 
×10-23) in order to assess the range of confidence in this microarray dataset. 
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The selected lncRNAs for technical and biological qPCR-based validation (Supplementary Table S5) 
were FEZF1-AS1, LINC01214, LINC00673, PCAT6, NUTM2A-AS1, RNF139-AS1, LINC01929, HMGA1P4 
(upregulated) and PCAT19, FENDRR, SVIL-AS1, LANCL1-AS1, ADAMTS9-AS2 and LINC00968 
(downregulated). 
Out of the 8 over-expressed lncRNAs identified on the microarray, 6 were confirmed as upregulated 
in lung tumours compared with paired normal tissue both in the technical and biological sets (Fig. 1). 
HMGA1P4 showed no significant difference in expression between tumour and normal paired 
samples in any of the validation sets (p>0.05 in both), whereas RNF139-AS1 showed insignificant 
expression difference in the technical validation set (p=0.325) and borderline difference in the 
biological validation set (p=0.03). All 6 selected under-expressed lncRNA targets were significantly 
differentially expressed in lung tumours compared with paired normal lung in both sets (Fig. 2). 
In order to estimate the efficiency of each validated target to discriminate between normal and 
tumour tissue, binary logistic regression analysis was performed and ROC curves were constructed 
(Supplementary Fig. S2). Expression of LANCL1-AS1 appeared to discriminate best (AUC=0.995, 95% 
CI: 0.987 - 1), whilst assessment of NUTM2A-AS1 was the least informative (AUC=0.689, 95% CI: 
0.594 – 0.784). 
Correlation between clinical data and the expression of the validated lncRNAs 
qPCR-based expression was analysed in relation to the epidemiological and clinicopathopathological 
parameters. No association with age or histology was observed, while a number of borderline 
associations between individual lncRNA expression and certain clinicopathological parameters were 
noticed (Table 1). Higher expression of FEZF1-AS1 (p=0.03) and ADAMTS9-AS2 (p=0.03) was 
observed in males compared to females. In addition, the expression of LINC00968 (p=0.03) was 
significantly higher in patients with lymph node involvement (N1/N2 stages when compared with 
N0), while the opposite relationship was found for LINC01929 (p=0.05). Finally, PCAT6 (p=0.02) and 
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LANCL1-AS1 (p=0.01) expression was significantly lower in poorly differentiated tumours when 
compared to well and moderately differentiated ones. 
Only the expression of LINC01214 and FENDRR appeared to have an effect in survival 
(Supplementary Fig. S3). Longer survival was observed among the patients with high LINC01214 
expression level (mean survival time: 73.24 months, 95% CI: 52.12 to 94.35) compared to low 
LINC01214 level (mean survival time: 41.14 months, 95% CI: 23.22 to 59.05, log rank p = 0.031). 
Likewise, patients with high FENDRR expression levels showed a better outcome (mean survival 
time: 75.29 months, 95% CI: 49.90 to 100.69) than those with low FENDRR expression levels (mean 
survival time: 43.71 months, 95% CI: 28.65 to 58.78, log rank p = 0.021). 
Cross-validation of selected targets with TCGA datasets 
Out of the 14 lncRNAs selected for validation in our study, 13 were confirmed as being differentially 
expressed between tumour and normal tissue in the TCGA dataset (Supplementary Fig. S4 and S5). 
The only significant difference between our dataset and TCGA was for RNF139-AS1; only a borderline 
expression difference was seen in our biological validation set (p=0.03), but it was significantly 
higher in tumours compared to normal tissues in the TCGA set (p=1.27x10-22). 
A number of significant associations were observed between tumour histology and the expression of 
the validated lncRNAs (Supplementary Fig. S6). Adenocarcinomas showed a significantly higher 
expression for PCAT19 (p=4.14x10-18), FENDRR (p=0.011), LANCL1-AS1 (p=1.26x10-4), LINC00968 
(p=3.97x10-12) and ADAMTS9-AS2 (p=1.92x10-44) when compared to squamous cell carcinomas. On 
the other hand, the expression of LINC00673 (p=6.42x10-30), PCAT6 (p=1.01x10-7), NUTM2A-AS1 
(p=3.69x10-5) and LINC01929 (p=3.26x10-6) was significantly higher in squamous cell carcinomas than 
in adenocarcinomas. 
Tumour stage significantly associated with the expression of LINC00673 (p=0.005), LINC01929 
(p=0.002), PCAT19 (p=0.001), FENDRR (p=8.33x10-6), SVIL-AS1 (p=0.037), LANCL1-AS1 (p=8.69x10-7), 
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LINC00968 (p=2.32x10-7) and ADAMTS9-AS2 (8.29x10-6) as determined by Kruskal-Wallis test 
(Supplementary Fig. S7). Dunn’s post hoc pairwise test revealed that median expression level was 
significantly lower in T1 compared to T2 stage tumours for LINC00673 (p=0.004) and LINC01929 
(p=0.001). SVIL-AS1 median expression was significantly lower in T1 compared to T3 NSCLC tumours 
(p=0.027). On the other hand, for PCAT19, FENDRR, LANCL1-AS1, LINC00968 and ADAMTS9-AS2 the 
median expression level was significantly higher in T1 compared to T2 (p-values ≤ 0.001) and in T1 
compared to T3 stage tumours (p-values ≤0.01) (Supplementary Fig. S7). 
Regarding nodal stage (Supplementary Fig. S8), the expression of LINC00673 (p=0.021) was 
significantly higher in patients with lymph node involvement (N1/N2 stages when compared with 
N0), while the opposite relationship was found for LANCL1-AS1 (p=0.001), LINC00968 (p=0.009) and 
ADAMTS9-AS2 (p=0.003). 
The expression of FEZF1-AS1 and LINC01929 appeared to be related to survival in the TCGA dataset 
(Supplementary Fig. S9). A trend for longer survival was observed among the patients with high 
FEZF1-AS1 level (mean survival time: 92.65 months, 95% CI: 74.46 to 110.84) compared to the low 
FEZF1-AS1 expression group (mean survival time: 76.25 months, 95% CI: 62.81 to 89.69, log rank p = 
0.040). In addition patients with low LINC01929 expression levels had better outcome (mean survival 
time: 95.38 months, 95% CI: 79.03 to 111.73) than those with high expression (mean survival time: 
67.68 months, 95% CI: 59.63 to 75.73, log rank p = 0.022). 
Expression of the validated lncRNAs in NSCLC cell lines 
The expression profiles of the 12 validated lncRNAs were also assessed in a panel of 13 lung cancer 
cell lines in comparison to a normal lung fibroblast line (IMR-90). Expression of the 6 downregulated 
targets in lung cancer tissue was significantly reduced (SVIL-AS1, FENDRR, ADAMTS9-AS2) or 
completely absent (PCAT19, LANCL1-AS1 and LINC00968) (Fig. 3) in lung cancer cell lines while 
positive controls (pooled normal lung tissue RNA) performed as expected in these experiments. 
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All the lncRNAs found upregulated in lung cancer tissue were widely expressed in the lung cancer 
cell lines analysed, however, not all of them followed the tissue pattern. When compared with the 
non-tumorigenic IMR-90, the expression of FEZF1-AS1, LIN00673 and LINC01214 was markedly 
higher in most lung cancer cell lines; the expression of PCAT6 and LINC01929 was strikingly lower 
and no clear trend was observed for the expression of NUTM2A-AS1 (Fig. 3). 
Methylation of lncRNA loci in NSCLC patients 
Only 7 out of the 14 lncRNAs selected from the microarray phase harbour a CpG island in their 
promoter. Pyrosequencing analysis demonstrated that PCAT6, RNF139-AS1, LINC00673 and 
NUTM2A-AS1 had <5% DNA methylation levels in both normal or tumour tissue, which is usually 
classified as noise.25 In contrast, variable methylation levels were observed for the remaining three 
targets. Hypermethylation in tumours (defined as >95% reference range of normal values) was 
observed in 45/126 (35.7%) of tumours for FENDRR, 61/128 (47.7%) for FEZF1-AS1 and 26/128 
(20.3%) for SVIL-AS1 (Fig 4). DNA and corresponding RNA was available for 42 common samples 
between the two (expression and methylation analysis) sets. No direct correlation was established 
between RNA expression and hypermethylation status in any of these three genes. 
Association between clinical data and the methylation of the validated lncRNAs 
FENDRR hypermethylation was more frequent in adenocarcinomas (56.9%) than in squamous cell 
carcinomas (21.6%, p=5.5x10-5) while an opposite borderline trend was found for FEZF1-AS1 (37.3% 
vs 55.3%, p=0.05, Table 2). Non-significant trends were found between, FEZF1-AS1 (p=0.08) and 
SVIL-AS1 (p=0.06) hypermethylation and the differentiation status of the tumours, while no 






The discovery of long non-coding RNAs has revolutionized biological research, from basic gene 
function to clinical exploitation as disease specific biomarkers or therapeutic targets. The lncRNA 
transcriptome constitutes a whole new level of regulation in cell physiology. The promise of 
utilization of lncRNAs in translational research and clinical management will rely on validation of 
differential gene expression levels associated with clinically relevant disease states and outcomes. 
Although there is still a lot to learn about lncRNA biology, there are already an increasing number of 
attempts to address lncRNA detection in body fluids to assist lung cancer diagnosis.26 
The existing lncRNA profiling data in lung cancer to date is substantial. This includes high-throughput 
approaches13, 14, 16-18 and targeted studies.27-31 However, despite the plethora of reports, the 
landscape is less clear than one would hope. The main reason is the marked diversity of approaches 
and validation methods. In addition, with the exception of studies mining existing data in the public 
domain, most studies utilize limited discovery sample sets, which leads to high false discovery rates 
(FDR). 
In this study, we aimed to strengthen the existing data and contribute to a more comprehensive 
landscape of lncRNA dysregulation in NSCLC. We used a comparatively large discovery set in 
microarray analysis (44 pairs) and performed both technical (29 pairs) and independent biological 
(38 pairs) validation of targets by RT-qPCR, in order to identify lncRNA profiles significantly 
distinguishing NSCLCs tissue from paired normal lung tissue. 
Following microarray data analysis and having set the desired thresholds (adjusted p-value (FDR) 
<0.01 and absolute log2 fold-change >0.5) we selected targets for validation with different p-values 
and fold-change values, in order to obtain a representative estimation of validity for our microarray 
analysis. An important selection factor was gene annotation and verification of probe sequences 
against locus sequence. For validation, we only selected among targets for which we had cross-
referenced the hybridization probe in the microarray with the annotated gene name in the 
databases (NCBI Genbank and ENSEMBL). Twelve out of the 14 targets selected for qPCR validation 
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(6 up- and 6 down-regulated in tumours) were successfully validated to demonstrate a strong and 
consistent difference of expression between NSCLC tissue and normal lung, suggesting a role in lung 
cancer pathogenesis. Interestingly, the two targets that failed in validation did not represent the 
highest p-values in the microarray analysis, indicating that even 10-2 adjusted p-values can be 
trusted. Surprisingly, a target with a very low p-value in microarray analysis (10-19) failed to validate, 
probably indicating potential problems with probe specificity and/or target annotation. 
To the best of our knowledge, from the 12 validated lncRNAs, this is the first study where LANCL1-
AS1, LINC01214, LINC01929, NUTM2A-AS1, PCAT19 and SVIL-AS1 are shown to be aberrantly 
expressed in cancer, while ADAMTS9-AS2, FENDRR, FEZF1-AS1, LINC00673, LINC00968 and PCAT6 
have been previously reported to be dysregulated in lung and other types of cancer. Interestingly, 
our analysis of the available TCGA datasets demonstrated that all the 12 targets show significant 
differential expression in NSCLC, increasing further the confidence in this result. Apart from the 
validation of the RNF139-AS1, the main difference between our dataset and TCGA is centred around 
clinicopathological associations. A substantial number of associations of these lncRNA targets were 
found in TCGA, while we only found a few associations of borderline significance. This is not 
surprising, as TCGA datasets contained 850 tumours as opposed to 67 for our set used for 
clinicopathological comparisons. The clinicopathological associations revealed within the TCGA 
dataset point to future research in establishing the potential prognostic value of these targets. In 
addition, no major associations were found between lncRNA expression and overall survival, with 
the exception of a few statistical trends (0.02<p<0.05) for FEZF1-AS1 and LINC01929 in TCGA dataset 
and LINC01214 and FENDRR in our dataset. The differences in this finding probably reflects the size 
difference of the two datasets. Nevertheless, one has to consider that overall survival in lung cancer 
is a challenging parameter as the cause of death is frequently related to comorbidities and/or 
therapy related toxicity.  
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ADAMTS9-AS2 was previously found dysregulated in several cancer types including NSCLC.32, 33 
Overexpression of ADAMTS9-AS2 reduces proliferation, cell migration, invasion, and induces 
apoptosis in vitro while restrains tumour growth in vivo.32-34 Recent evidence suggests that 
ADAMTS9-AS2 might exert its function by ‘sponging’ common microRNAs.33, 34 For instance, in 
NSCLC, ADAMTS9-AS2 represses cancer progression by regulating the miR-223-3p/TGFBR3 axis33, 
while in ovarian cancer it regulates the miR-182-5p/FOXF2 pathway.34 
A few studies have analysed the role of FENDDR in various cancer types suggesting that FENDRR 
plays an inhibitory role in tumour progression by regulating cell migration, invasion and 
metastasis.35-37 FENDRR was found to be downregulated in gastric cancer tissues, which increased 
cell migration and invasion in vitro through up-regulation of FN1 and MMP2 and MMP9.35 FENDRR 
expression was also shown to be suppressed in gastric cancer associated fibroblasts (CAFs) by 
hypermethylation.38 In NSCLC, we have observed that FENDRR expression is reduced in lung tumours 
compared with paired normal tissue and lung cancer cell lines showed a similar trend. This result is 
in agreement with a previous study reporting a significant downregulation of FENDRR in NSCLC as 
well as a potential involvement of FENDRR in regulating epithelial mesenchymal transition (EMT), 
stemness, and metastasis of lung cancer cells via EZH2.37 
Our finding on FEZF1-AS1 upregulation in NSCLC is in agreement with previous reports on many 
tumour types including NSCLC39, 40 and breast.41 FEZF1-AS1 exerts regulatory functions at a 
transcriptional and post-transcriptional level, promoting cell proliferation, migration, and invasion. 
In fact, it has been reported to modulate the expression of Nanog by sponging miR-30a to promote 
cancer stemness in breast cancer.41 However, FEZF1-AS1 can also act at a transcriptional level by 
recruiting chromatin-modifying enzymes to target genes. For instance, FEZF1-AS1 can bind to LSD1 
and EZH2 and epigenetically repress E-cadherin in NSCLC39 or p57 in lung adenocarcinomas.40 
In our dataset, LINC00673 was overexpressed in lung tumours, which is in agreement with previous 
reports on NSCLC.42-44 Upregulation of LINC00673 has also been reported in gastric cancer45, 46, 
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having a role in cell proliferation, migration, and invasion. LINC00673 transcripts have been localized 
both in the nucleus and the cytoplasm,42, 44-46 suggesting that it can function at a transcriptional and 
post-transcriptional level. In NSCLC, Lu et al proposed that LINC00673 promotes TGF-β induced EMT 
by sponging miR-150-5p and thereby modulating ZEB1 expression indirectly.43 In addition, Roth et al 
have reported that LINC00673 negatively regulates p53 translation by directly interacting with its 
3’UTR leading to senescence bypass.44 LINC00673 can also regulate the expression of target genes 
epigenetically. Notably, in lung cancer, LINC00673 represses HOXA5 expression through recruiting 
the epigenetic repressor EZH2 to its promoter region.47 Shi et al observed that LINC00673 
epigenetically inhibited NCALD expression through direct binding to LSD1.42 In a similar way, in 
gastric cancer LINC00673 suppressed KLF4 expression by interacting with EZH2 and DNMT146 and 
direct binding to LSD1 and EZH2 repressed KLF2 and LATS2 expression.45 
Regarding PCAT6, our findings are in line with previous studies reporting its upregulation in various 
cancer types including NSCLC48 and colon.49 Functional studies have shown that PCAT6 exerts its 
oncogenic activity, at least partly, by leading chromatin-modifying complexes to specific promoter 
regions. For instance, in NSCLC, PCAT6 interacts with EZH2 epigenetically, suppressing LATS248, while 
in colon cancer, the association of PCAT6 with EZH2 modulates ARC expression.49 
We observed that LINC00968 was significantly downregulated in lung tumours compared with paired 
normal lung and completely absent in lung cancer cell lines, which is in contrast to a previous study 
reporting upregulation of LINC00968 in NSCLC.50 However, that study evaluated LINC00968 
expression using datasets from the Oncomine database and 4 NSCLC cell lines, whereas we 
performed wet validation in 82 NSCLC tissue samples and 13 NSCLC cell lines. We speculate that 
inconsistency of results may lie with incorrect annotation in the previous bioinformatic analysis. 
To explore the molecular mechanisms responsible for the modulated expression observed, we 
hypothesized that DNA methylation might be one of the mechanisms responsible. Therefore, we 
undertook DNA methylation analysis in 7 of our target genes that were found to bear a CpG island in 
17 
 
their promoter. Of those, hypermethylation was detected only in three, namely FENDRR, SVIL-AS1 
and FEZF1-AS1. There was a general lack of correlation between expression and DNA methylation in 
the genes tested. This may be due to the low number of common samples in the two analyses, but it 
most likely indicates the presence of strong alternative regulation factors besides DNA methylation. 
FENDRR hypermethylation has previously been shown in gastric cancer associated fibroblasts 
(CAFs).38 FENDRR promoter methylation demonstrated a significant increase in adenocarcinoma, 
however this was not the case for FENDRR expression. 
This study contributes significantly to the wider knowledge of lncRNA involvement in NSCLC 
pathogenesis. Its strength lies with the technical and independent biological validation in patient 
tissues as well as its agreement with the available relevant TCGA datasets. Out of the 12 validated 
targets, half are shown to be differentially expressed in cancer for the first time, while our results for 
the other six lncRNAs confirm previous findings. Certainly, there are still a large number of 
dysregulated candidate lncRNAs in our microarray analysis list that require independent validation. 
Our data have been made publicly available, therefore open to other research groups to attempt 
independent validation. To date, the involvement of lncRNAs in NSCLC development is undisputable; 
however, further studies are needed to establish additional lncRNA targets and to identify their 
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Figure 1. Scatterplot diagrams demonstrating the expression levels of lncRNAs FEZF1-AS1 (A), 
LINC01214 (B), LINC00673 (C), PCAT6 (D), LINC01929 (E) and NUTM2A-AS1 (F), which are 
overexpressed in lung tumours compared to adjacent normal lung tissue. Means are also indicated 
along with the 95% confidence intervals. Technical validation values are given by circles, while 
biological independent validation values are given as triangles. p-values are derived from Wilcoxon 
ranked tests. RQ: relative quantity. 
Figure 2. Scatterplot diagrams demonstrating the expression levels of lncRNAs PCAT19 (A), SVIL-AS1 
(B), LANCL1-AS1 (C), FENDRR (D), LINC00968 (E) and ADAMTS9-AS2 (F), which are downregulated in 
lung tumours compared to adjacent normal lung tissue. Means are also indicated along with the 95% 
confidence intervals. Technical validation values are given by circles, while biological independent 
validation values are given as triangles. p-values are derived from Wilcoxon ranked tests. RQ: 
relative quantity. 
Figure 3. Bar chart diagrams showing the expression levels of the validated lncRNAs in NSCLC cell 
lines and a normal lung fibroblast cell line (IMR90), which was used as a calibrator (RQ=1) for the 
analysis, with the exception of FEZF1-AS1 and LINC01929, which are not expressed in IMR90. In this 
case Calu-1 was used as calibrator. All downregulated lncRNAs in lung cancer tissue were reduced 
(SVIL-AS1 (A), FENDRR (B), ADAMTS9-AS2 (C)) or completely undetected (PCAT19, LANCL1-AS1 and 
LINC00968, data not shown). Upregulated in lung cancer tissue lncRNAs did not necessarily follow 
the same pattern in cell lines. FEZF1-AS1 (D), LIN00673 (E) and LINC01214 (F) were higher in NSCLC 
cell lines, PCAT6 (G) and LINC01929 (H) were lower in NSCLC cell lines compared to IMR90, while 
NUTM2A-AS1 (I) was highly variable. Error bars represent standard error of the mean. RQ: relative 
quantity. 
Figure 4. Scatterplot diagrams demonstrating the DNA methylation levels of lncRNAs FENDRR (A), 
FEZF1-AS1 (B) and SVIL-AS1 (C) in lung tumours compared to adjacent normal lung tissue. The 
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horizontal dotted line in each diagram defines the 95% reference range (= mean +2 × Standard 











(RQ) Mann-Whitney test 





Male 49 6.49 8.31 
268 0.03 Female 17 2.72 3.68 
ADAMTS9-
AS2 
Male 50 0.66 1.51 
255 0.03 














N(-) 33 31.63 74.00 
339 0.05 
N(+) 29 8.00 7.39 
LINC00968 
N(-) 34 0.20 0.50 









Poor 18 2.03 3.85 
212 0.02 
Well-Moderate 38 3.60 5.83 
LANCL1-AS1 
Poor 20 0.02 0.05 
266 0.01 
Well-Moderate 41 0.07 0.11 
Abbreviations: SD, standard deviation 
Table 2. Association between clinical data and hypermethylation status of FENDRR and FEZF1-AS1. 








AdenoCa 51 29 (56.9%) 
5.5 ×10-5 
SqCCa 74 16 (21.6%) 
FEZF1-AS1 
AdenoCa 51 19 (37.3%) 
0.05 









Poor 36 12 (34.3%) 
0.08 
Well-Moderate 87 45 (51.7%) 
SVIL-AS1 
Poor 35 11 (31.4%) 
0.06 
Well-Moderate 87 14 (16.1%) 
Abbreviations: AdenoCa, adenocarcinoma; SqCCa, squamous cell carcinoma 
 
